Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting No phase listed Observational

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

ClinicalTrials.gov ID: NCT06652100

Public ClinicalTrials.gov record NCT06652100. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults (EPACRA-AKI)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.

Study identification

NCT ID
NCT06652100
Recruitment status
Active, not recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
BioPorto Diagnostics
Industry
Enrollment
800 participants

Conditions and interventions

Interventions

Diagnostic Test

Eligibility (public fields only)

Age range
22 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 27, 2024
Primary completion
Jan 29, 2026
Completion
Jan 30, 2026
Last update posted
Nov 18, 2025

2024 – 2026

United States locations

U.S. sites
12
U.S. states
12
U.S. cities
12
Facility City State ZIP Site status
The University of Alabama Birmingham Alabama 35233
UC Davis Sacramento California 95817
Yale University New Haven Connecticut 06510
University of Chicago Chicago Illinois 60637
Johns Hopkins University Baltimore Maryland 21224
Massachusetts General Hospital Boston Massachusetts 02114
University of Michigan Ann Arbor Michigan 48109
University of New Mexico Albuquerque New Mexico 87131
Columbia University New York New York 10032
Wake Forest University Winston-Salem North Carolina 27109
Cleveland Clinic Cleveland Ohio 44195
Medical University of South Carolina Charleston South Carolina 29425

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06652100, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2025 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06652100 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →